Detailed explanation of the therapeutic mechanism of ensidipine IDH2 inhibitor

Enasidenib is a selective IDH2 inhibitor specifically developed for the treatment of patients with acute myeloid leukemia (AML) carrying IDH2 mutations. The IDH2 gene encodes isocitrate dehydrogenase 2, an important enzyme involved in cellular energy metabolism and epigenetic regulation. When specific mutations occur in IDH2, its enzyme activity will be abnormal, causing α-ketoglutarate (α-KG) to be converted into an abnormal metabolite-2-hydroxyglutarate (2-HG). 2-HG inhibits a variety of α-KG-dependent dioxygenases at high concentrations, affecting the demethylation process of DNA and histones, causing hematopoietic cells to stay in an immature state and unable to differentiate into normal blood cells. This process is considered to be one of the important pathogenic mechanisms of AML.

The mechanism of action of ensidipine is precisely aimed at this molecular pathological link. It can bind to mutantIDH2 enzyme and block its abnormal catalytic activity, thereby reducing the production of 2-HG. As the level of 2-HG decreases, the inhibited demethylase activity is restored, and the hematopoietic stem/progenitor cells regain their differentiation ability and gradually mature into normal-functioning myeloid cells. This mechanism is different from the way traditional chemotherapy kills proliferating cells. Ensidipine is more like a "differentiation induction" treatment, allowing abnormally stagnant cells to return to the normal development track. Therefore, during the treatment process, it is often seen that the white blood cell count first increases and then stabilizes.

In clinical studies, ensidipine has shown inhibitory effects on multiple IDH2 mutation subtypes, including R140Q and R172K mutations, which are more common in AML patients. It is worth noting that the therapeutic response to ensidipine often takes weeks to months to appear because the differentiation process is gradual, which requires patients and doctors to be patient during the medication process and to closely monitor the blood picture and possible risk of differentiation syndrome.

As an important representative of medicine, the emergence of ensidipine not only brings new treatment options to patients with relapsed or refractory AML, but also promotes the development of targeted drugs for abnormal tumor metabolism.

Reference materials:https://www.idhifa.com/